文摘

目的:眼部重症肌无力是一种亚型重症肌无力,导致相对温和的残疾,但可能转换成严重的普遍的肌肉无力。眼部重症肌无力的通用管理计划还未确定。这项研究来确定执行的结果目前眼部重症肌无力的治疗选择。方法:回顾性分析78年眼重症肌无力患者平均疾病持续时间8.3(范围0.5 - -58.3)年。结果:54例(69%)症状和体征仍局限于眼外肌肉在观察期内。剩下的24例(31%)出现症状的全面重症肌无力;50%的人在两年内,75%在四年后发病。概括的风险有所降低被发现在那些轻微的症状,正常神经重复刺激测试和低或没有antiacetylcholine受体(乙酰胆碱受体抗体在诊断时)。接受免疫抑制治疗的患者(糖皮质激素和/或咪唑硫嘌呤)很少开发普遍重症肌无力(六50,12%)。那些没有这样的待遇,通常由于不确定诊断和转诊,转化为普遍重症肌无力更经常(18 28,64%)。 CONCLUSIONS: The prognosis of ocular myasthenia gravis is good. A conventional scheme with short-term corticosteroids and long-term azathioprine seems adequate to achieve remission in most patients. The proportion of patients developing generalised myasthenia gravis was smaller in this population compared with previously published groups (usually 50%-70%). Early immunosuppressive treatment is at least partially responsible for this finding. Thymectomy (performed here in 12 patients with an abnormal chest CT) also correlated with a good outcome, but had no apparent advantage over medical treatment alone.